igem logo

Cloning, expression and characterization of ELPs


To make our bacteria more controllable in a therapy we wanted to prevent them from dividing. We designed a sequence of Elastin-Like Polypeptides (ELPs) that could theoretically form a hydrogel within the cells, which would inhibit division.

We needed to come up with a way to crosslink the system to make the interactions strong enough to form a stable hydrogel. There were two strategies that we wanted to try and they involved constructing a triblock ELP containing a (relatively) hydrophilic core sequence, sandwiched by two hydrophobic outer sequences. These sequences can be seen below. To the end of each hydrophobic block, a crosslinking group is attached differing for both strategies. We wanted to include and test both methods to have a higher chance of succeeding. We used Leucine zippers Z1 and Z2 and rapamycin binding domains. A schematic representation of what the constructs look like can be seen in Figure 1. All the different parts of the constructs can be seen in Table 1.


Figure 1: Overview of all different constructs that were designed and built. The hydrophobic I[60] fragments interact with each other through hydrophobic interactions. Z1 and Z2 (dark and light yellow, respectively) are also able to interact, both via hydrophobic and electrostatic interactions. Lastly, FKBP12 (pink) and FRB (red) are both able to bind rapamycin (yellow)

Construct Name
Z1-A120-Z2 BBa_K4905006
Z2-A120-Z2 BBa_K4905008
FRB-A120-FRB BBa_K4905014
FRB-A120-FKBP12 BBa_K4905012
FKBP12-A120-FKBP12 BBa_K4905010
Z1-A100-Z2 BBa_K4905007
Z2-A100-Z2 BBa_K4905009
FRB-A100-FRB BBa_K4905015
FRB-A100-FKBP12 BBa_K4905013
FKBP12-A100-FKBP12 BBa_K4905011

Table 1: Overview of all constructs that were made with links to their part pages. to simplify the names of all constructs, the hydrohpobic regions (I[60]) have been omitted from the construct names.

First, existing ELP gene sequences that were already present at our university and provided to us by Dr. Le, were digested and ligated to create two constructs with different hydrophilic linkers of which the gels can be seen in Figure 2, as described in more detail in Week 20 of the Notebook. The hydrophobicity of the ELPs is determined by their guest residue as is also described in the Project Description. These linkers contain the guest residues Alanine (A) and Glycine (G), one with 20 repeats of VPGAG[3]VPGGG[2] and one with 24 repeats of this same segment. These sequences are called A[100] and A[120], respectively. Both of these hydrophilic linkers contain hydrophobic segments at their ends, where the guest residue is Isoleucine (I). The hydrophobic sequence looks as follows: VPGIG[60], abbreviated as I[60]. Successful ligation was confirmed by a double digestion with restriction enzymes at either ends of the constructs (Figure 1B). In addition, the plasmids were sequenced by Sanger sequencing (Azenta). Next, our gBLocks (FRB, FKBP12, Z1 and Z2) were cloned into an empty pET24a(+) vector. This was confirmed by colony PCR and sequencing of the plasmids. They were then combined with A[100] and A[120] to give us our final constructs that can be seen in Figure 1 and Table 1. Successful ligation was confirmed for each construct through means of sequencing.


Image 1
Image 2

Figure 2: A) digestion of the three different ELP sequences. 1) I[60]A[60] (3691 bp) 2) A[40]I[60] (4874 bp) 3) and A[60]I[60] (5174 bp). B) Double digestion of the complete ELP fragments, from the purified plasmids, confirming successful ligation. expected lengths are 3300 bp and 3600 bp for A[100] and A[120], respectively.

After successfully creating the plasmids containing our desired constructs, we expressed them in E. coli BL21(DE3). However, the A[100] constructs lagged behind with cloning, so only the A[120] constructs were expressed. Because we managed to form a gel with these constructs, as seen in the Hydrogel Formation paragraph, the decision was made not to express the A[100] constructs to save time. We then purified all constructs using inverse transition cycling, a process in which the Tt of the ELPs is utilized to separate them from cellular debris and other proteins. Afterwards, dialysis was performed to get rid of any residual salt from the inverse transition cycling. We managed to purify all but one construct, namely FKBP12-A120-FKBP12 (Figure 3). The latter protein was not expressed at all, as evidenced by the gel containing the lysate in Week 28 of the Notebook. Since this was the only protein containing FKBP12 at its N-terminus, this sequence might somehow interfere with the expression. The products that were purified were then freeze-dried and stored at -20 °C until further use. The average yield of the Z1/Z2 constructs was 150 mg/L culture, whereas for the FRB/FKBP12 constructs it was 50 mg/L.

Construct Expected Molecular weight (kDa) Number in gel
Z1-A120-Z2 105.1 1
Z2-A120-Z2 105.0 2
FRB-A120-FRB 120.5 3
FKBP12-A120-FKBP12 122.5 4
FRB-A120-FKBP12 121.5 5

Image 3
Figure 3: SDS-PAGE of the five constructs that were expressed and purifed. Only FKBP12-A120-FKBP12 was not expressed.

Characterization of our in situ gelation within cells with the use of fluorescence recovery after photobleaching (FRAP) microscopy required us to design a model protein which could interact with the hydrogel, and which we could visualize under the confocal microscope. We decided to use VPGIG[60]-mNeonGreen. . The fluorescenct protein would have a lower diffusion rate after bleaching compared to non-hydrogelation situation. We cloned the gene fragment into a pBAD vector under the control of an arabinose promoter, to allow for orthogonality between this vector and the pET24a(+) vector encoding the zipper-ELP construct. Successful cloning was verified by a double digestion of the plasmids as well as sequencing.

However, to our surprise, the sequencing results indicated that instead of a VGPIG[60] fragment, the mNeonGreen was attached to a VPGAG[3]VPGGG[2][12] fragment, which is hydrophilic, relative to the VPGIG[60] fragment. This is likely due to a labeling mistake by a previous user of the plasmid. Due to a lack of time, we decided to continue using this construct in our microscopy experiments as a model protein to monitor the diffusion of proteins within the gelated bacteria. The results of our digestion can be seen in Figure 4.


Image 12
Figure 4: Double digestion by BamHI-HF/XbaI of pBAD vector containing [A3G2][60]-mNeonGreen. The expected mass of the gene fragment is 1674 bp.

Z1-A120-Z2 and [A3G2][12]-mNeonGreen were co-expressed in E. coli BL21(DE3), as is described in week 36 and 37 of the Notbeook. . SDS-PAGE was then used to confirm the presence of both proteins. The results of this can be seen in Figure 5. After some trial and error using different conditions for the co-expression, we managed to express both the ELPs, as well as the fluorescent protein. E. coli containing both proteins were then used for FRAP microscopy of which the results are found here.


The bacteria containing Z1-A120-Z2 and [A3G2][12]-mNeonGreen were then used to determine if diffusion throughout the cell was affected by the formation of the gel. This was done by using Fluorescence recovery after photobleaching (FRAP). We hypothesized that once the gel is formed intracellularly, the diffusion rate is negatively affected due to an increase of viscosity of the cytosol. More about this can be read here.

Image 13
Image 14

Figure 5: A) SDS-PAGE gel showing the co-expressed proteins (left three lanes) versus a negative control in which no arabinose was added and therefore no expression of [A3G2]60-mNeonGreen was induced (right three lanes). B) Bacterial cell pellet excited by a blue light transilluminator showing the fluorescence emitted by mNeonGreen.


Go back to results

[1] D. E. Meyer and A. Chilkoti, “Quantification of the effects of chain length and concentration on the thermal behavior of elastin-like polypeptides,” Biomacromolecules, vol. 5, no. 3, pp. 846–851, May 2004, doi: 10.1021/BM034215N/SUPPL_FILE/BM034215NSI20031125_032417.PDF.

[2] A. Fernández-Colino, F. J. Arias, M. Alonso, and J. C. Rodríguez-Cabello, “Amphiphilic Elastin-Like Block Co-Recombinamers Containing Leucine Zippers: Cooperative Interplay between Both Domains Results in Injectable and Stable Hydrogels,” Biomacromolecules, vol. 16, no. 10, pp. 3389–3398, Oct. 2015, doi: 10.1021/ACS.BIOMAC.5B01103/ASSET/IMAGES/LARGE/BM-2015-011033_0009.JPEG.

[3] M. V. Blagosklonny, “Cancer prevention with rapamycin,” Oncotarget, vol. 14, no. 1, pp. 342–350, 2023, doi: 10.18632/oncotarget.28410.

[4] X. Yang, Y. Zhong, D. Wang, and Z. Lu, “A simple colorimetric method for viable bacteria detection based on cell counting Kit-8,” Anal. Methods, vol. 13, no. 43, pp. 5211–5215, Nov. 2021, doi: 10.1039/D1AY01624E.

[5] E. L. Foltz, J. W. West, I. H. Breslow, and H. Wallick, “Clinical pharmacology of pivampicillin.,” Antimicrob. Agents Chemother., vol. 10, no. 3, pp. 442–454, 1970, doi: 10.47363/jprsr/2022(3)129.

[6] E. Israeli, B. T. Shaffer, and B. Lighthart, “Protection of Freeze-Dried Escherichia coli by Trehalose upon Exposure to Environmental Conditions,” Cryobiology, vol. 30, no. 5, pp. 519–523, Oct. 1993, doi: 10.1006/CRYO.1993.1052.

[7] Poudyal, R. R., Guth-Metzler, R., Veenis, A. J., Frankel, E. A., Keating, C. D., & Bevilacqua, P. C. (2019). Template-directed RNA polymerization and enhanced ribozyme catalysis inside membraneless compartments formed by coacervates. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-08353-4

[8] C. Pöhlmann et al., “Periplasmic Delivery of Biologically Active Human Interleukin-10 in Escherichia coli via a Sec-Dependent Signal Peptide,” J. Mol. Microbiol. Biotechnol., vol. 22, no. 1, pp. 1–9, Apr. 2012, doi: 10.1159/000336043.

[9] J. Pille, S. A. M. Van Lith, J. C. M. Van Hest, and W. P. J. Leenders, “Self-Assembling VHH-Elastin-Like Peptides for Photodynamic Nanomedicine,” Biomacromolecules, vol. 18, no. 4, pp. 1302–1310, Apr. 2017, doi: 10.1021/ACS.BIOMAC.7B00064/ASSET/IMAGES/LARGE/BM-2017-00064P_0004.JPEG.

[10] T. Tian, Z. Wang, and J. Zhang, “Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies,” 2017, doi: 10.1155/2017/4535194.

[11] M. Krzystek-Korpacka, R. Kempiński, M. A. Bromke, and K. Neubauer, “Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review,” Diagnostics 2020, Vol. 10, Page 601, vol. 10, no. 8, p. 601, Aug. 2020, doi: 10.3390/DIAGNOSTICS10080601.